SCHEMBL2092853

SCHEMBL2092853

COc1ccc(NC(=O)C[O])c(OC)c1

nearest known ligand 0.82

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.82
MAPT P10636 2/20 0.69
NPC1 O15118 2/20 0.66
RAB9A P51151 2/20 0.66
CYP1A2 P05177 2/20 0.66
CYP2C9 P11712 1/20 0.66
CYP2C19 P33261 1/20 0.66
HPGD P15428 2/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
KMT2A Q03164 2/20 0.62
CYP1A1 P04798 1/20 0.61
CYP1B1 Q16678 1/20 0.61
USP2 O75604 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
TAS1R3 Q7RTX0 1/20 0.59
TAS1R1 Q7RTX1 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6001770 0.88 ALDH1A1 (0.77) ALDH1A1MAPTNPC1RAB9ACYP1A2
SCHEMBL10852085 0.87 ALDH1A1 (0.82) ALDH1A1MAPTNPC1RAB9ACYP1A2
SCHEMBL2092856 0.87 ALDH1A1 (0.82) ALDH1A1MAPTNPC1RAB9ACYP1A2
SCHEMBL4542785 0.86 ALDH1A1 (0.85) ALDH1A1MAPTNPC1RAB9ACYP1A2
SCHEMBL2094905 0.86 ALDH1A1 (0.79) ALDH1A1MAPTNPC1RAB9ACYP1A2
SCHEMBL1494291 0.86 ALDH1A1 (0.79) ALDH1A1MAPTNPC1RAB9ACYP1A2
SCHEMBL7497883 0.86 ALDH1A1 (0.79) ALDH1A1MAPTNPC1RAB9ACYP1A2
SCHEMBL6001774 0.84 ALDH1A1 (0.77) ALDH1A1MAPTNPC1RAB9ACYP1A2
SCHEMBL19427445 0.83 ALDH1A1 (0.75) ALDH1A1MAPTNPC1RAB9ACYP1A2
SCHEMBL2094900 0.83 ALDH1A1 (0.75) ALDH1A1MAPTNPC1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ALDH1A1 412/4885MAPT 4299/4885NPC1 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.